Clinical Trial Update: Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial of enoblituzumab (MGA271) in men with localized intermediate- and high-risk prostate cancer; results were posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Enoblituzumab (MGA271) (enoblituzumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Prostate Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-08-24